Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice

Circulation: Cardiovascular Quality and Outcomes

Volumn 4, Issue 4, 2011, Pages 408-415

  Schafer, Pascha E ^a   Sacrinty, Matthew T ^a   Cohen, David J ^b   Kutcher, Michael A ^a   Gandhi, Sanjay K ^a   Santos, Renato M ^a   Little, William C ^a   Applegate, Robert J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

Clinical outcomes; Cost effectiveness; Dual antiplatelet therapy; Health economics; Stent therapy

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG ELUTING STENT; FEMALE; HEART MUSCLE REVASCULARIZATION; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; POSTOPERATIVE COMPLICATIONS; SIROLIMUS;

EID: 80054769770     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.110.960187     Document Type: Article

References (27)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, the SIRIUS Investigators: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323 (Pubitemid 37186209)
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, for the TAXUS-IV Investigators. One-year clinical results with the slowrelease, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV Trial. Circulation. 2004;109:1942-1947 (Pubitemid 38544483)
3. Applegate RJ, Sacrinty MT, Kutcher MA, Baki TT, Gandhi SK, Santos RM, Little WC. Comparison of drug-eluting versus bare metal stents on later frequency of acute myocardial infarction and death. Am J Cardiol. 2007;99:333-338 (Pubitemid 46149550)
4. Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, Lahue BJ, Clark MA, Lacey MJ, Russell ME, Ellis SG, Hermiller JB, Cox DA, Cohen DJ, TAXUS-IV Investigators. Cost-effectiveness of paclitaxeleluting stents for patients undergoing percutaneous coronary revascularization: Results from the TAXUS-IV trial. J Am Coll Cardiol. 2006;48: 253-261 (Pubitemid 44026660)
5. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carozza JP Jr., Zidar JP, Kuntz RE, SIRIUS Investigators. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation. 2004;110:508-514 (Pubitemid 39031165)
6. Roukoz H, Bavry AA, Sarkees ML, Mood GR, Kumbhani DJ, Rabbar MG, Bhatt DL. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med. 2009; 122:581.e1-581.e10
7. Simonton CA, Brodie B, Cheek B, Krainin F, Metzger C, Hermiller J, Juk S, Duffy P, Humphrey A, Nussbaum S, STENT Group. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: Results from a large prospective multicenter registry-STENT group. J Am Coll Cardiol. 2007;50:1214-1222 (Pubitemid 47405129)
8. Novack V, Cutlip D, Kleiman N, Pencina M, Mauri L, Yen CH, Berger P, Goldberg S, Kellett M, Waksman R, Hong M, Raizner AE, Cohen DJ. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxeleluting stents: Results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. J Am Coll Cardiol Cardiovasc Interv. 2009;2:767-775
9. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC. Three-year comparison of drug-eluting stents versus bare metal stents. J Am Coll Cardiol Interv. 2009;2:231-239
10. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Baki TT, Little WC. "Off-Label" stent therapy: 2-year comparison of drugeluting versus bare-metal stents. J Am Coll Cardiol. 2008;51:607-614 (Pubitemid 351193101)
11. American College of Cardiology-National Cardiovascular Data Registry Module Version 3.0. 2004. http://www.accncdr.com/webNCDR/NCDR Documents/datadictdefsonlyv30.pdf. American College of Cardiology
12. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, on behalf of the Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007;115:2344-2351 (Pubitemid 46685903)
13. Physicians' Desk Reference, 2005 Red Book. April 2006 ed. Montvale, NJ: Thomson Healthcare; 2006
14. Rinfret S, Grines CL, Cosgrove RS, Ho KK, Cox DA, Brodie BR, Morice MC, Stone GW, Cohen DJ, Stent-PAMI Investigators. Quality of life after balloon angioplasty or stenting for acute myocardial infarction: One-year results from the Stent-PAMI trial. J Am Coll Cardiol. 2001;38: 1614-1621 (Pubitemid 33065444)
15. Weaver WD, Reisman MA, Griffin JJ, Buller CE, Leimgruber PO, Henry T, D'Haem C, Clark VL, Martin JS, Cohen DJ, Neil N, Every NR. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): A randomised trial. Lancet. 2000; 355:2199-2203 (Pubitemid 30394327)
16. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
17. Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW, Grines CL. Cost-effectiveness of coronary stenting in acute myocardial infarction: Results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation. 2001;104:3039-3045 (Pubitemid 34014054)
18. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-1108 (Pubitemid 127453463)
19. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina: Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med. 1990;113:852-871
20. Cohen DJ, Breall JA, Ho KK, Kuntz RE, Goldman L, Baim DS, Weinstein MC. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: Use of a decision-analytic model. Circulation. 1994;89:1859-1874 (Pubitemid 24114266)
21. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann F-J, Fleckenstein M, Pfafferott C, Seyfarth M, Schomig A. Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) trial. Circulation. 2001;103: 2816-2821
22. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, Muller M, Dirschinger J, Schomig A. Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISARSTEREO- 2) Trial. J Am Coll Cardiol. 2003;41:1283-1288
23. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carozza JP, Cohen DJ, Kuntz RE. Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082-2089 (Pubitemid 36005891)
24. Greenberg D, Bakhai A, Neumann PJ, Cohen DJ. Willingness to pay for avoiding coronary restenosis and repeat revascularization: Results from a contingent valuation study. Health Policy. 2004;70:207-216 (Pubitemid 39201406)
25. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159-168 (Pubitemid 46089732)
26. Yusuf S, Zhao F, Mehta SR, Chrolavivius S, Tognoni G, Fox KK, the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494-502 (Pubitemid 32758501)
27. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol. 2004;43:513-518. (Pubitemid 38229518)